Arkolith/Insider Trading/ARWR/Form 4

Anzalone Christopher Richard

Chief Executive Officer, DirectorARROWHEAD PHARMACEUTICALS, INC. (ARWR) · full profile →Form 4 · filed Dec 30, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$3.6M
Net Open-Market Flow
-$3.6M
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 29, 2025Sell(S)17K$68.69$1.1M3.8M
Dec 29, 2025Sell(S)35K$69.33$2.4M3.8M
Dec 29, 2025Option exercise(M)17K$6.15$102K3.9M
Dec 29, 2025Option exercise(M)35K$6.15$216K3.8M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 29, 2025Option exercise(M)17K—$00
Dec 29, 2025Option exercise(M)35K—$017K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001423029-25-000009) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML